Karyopharm Therapeutics Inc. Securities Litigation
On or around 07/24/2019 (Ongoing date of last review)
Filing Date: July 23, 2019
According to the Complaint, Karyopharm is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer and other major diseases. During the Class Period, Karyopharm’s lead drug candidate was selinexor, an oral selective inhibitor of nuclear export for the treatment of cancer indications with significant unmet clinical need, initially to be used for the treatment of blood cancers.
The Complaint alleges that during the Class Period, Defendants falsely represented the safety and efficacy of selinexor. Specifically, the Complaint alleges Defendants' material misrepresentations and omissions center on Defendants' claims regarding results from clinical trials for selinexor's treatment of patients with certain types of blood cancer.
Company & Securities Information
Defendant: Karyopharm Therapeutics Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: KPTI
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Allegheny County Employees' Retirement System, et al. v. Karyopharm Therapeutics Inc., et al.
COURT: D. Massachusetts
DOCKET #: 19-CV-11597
DATE FILED: 07/23/2019
CLASS PERIOD START: 03/02/2017
CLASS PERIOD END: 02/22/2019
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Bernstein Litowitz Berger & Grossmann LLP (New New York) 1251 Avenue of the Americas, Bernstein Litowitz Berger & Grossmann LLP (New New York), NY 10020 (212) 554-1400 (212) 554-1448 ·
Block & Leviton LLP 155 Federal Street, Suite 1303, Block & Leviton LLP, MA 02110 (617) 398-5600 (617) 507-6020 ·
First Identified Complaint (FIC) Filings:
Class Action Complaint for Violations of the Federal Securities Laws
U.S. District Court Civil Docket
—Reference Complaint Complaint Related Data is not available
Related District Court Filings
—Related District Court Filings Data is not available